Trimethoprim-Sulfamethoxazole in the Treatment of Stenotrophomonas maltophilia Osteomyelitis | Zendy

Michael L. Landrum | Zendy; N. G. Conger | Zendy; Michael A. Forgione | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Trimethoprim-Sulfamethoxazole in the Treatment of Stenotrophomonas maltophilia Osteomyelitis

Author(s) -

Michael L. Landrum,

N. G. Conger,

Michael A. Forgione

Publication year - 2005

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/429730

Subject(s) - stenotrophomonas maltophilia , medicine , sulfamethoxazole , trimethoprim , osteomyelitis , microbiology and biotechnology , gram negative bacterial infections , stenotrophomonas , antibiotics , bacteria , pseudomonas , surgery , pseudomonas aeruginosa , genetics , biology

in 99 patients (79%) who received ribavirin for HCPS, and 26 (21%) required blood transfusions. Three subjects were withdrawn from the study because of pancreatitis. Although we agree that it can be difficult to obtain larger sample sizes in studies of rare infectious diseases (as evidenced by the low enrollment rate in the study of HCPS by Mertz et al. [1]), one should be clear about the limitations of the data imposed by smaller sample sizes when evaluating the safety, as well as the efficacy, of drugs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research